Compare VanEck Gold Miners ETF (GDX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Gilead Sciences, Inc. — how do they compare? VanEck Gold Miners ETF trades at $88.64 (market cap $25.65B), while Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 7.1× VanEck Gold Miners ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Gilead Sciences, Inc. for 111 Days on average.
| GDX | GILD | |
|---|---|---|
Market Cap | $25.65B | $182.40B |
Volume | 16,534,046 | 4,469,821 |
52-Week High | $115.84 | $155.80 |
52-Week Low | $68.28 | $116.74 |
Typical Hold Time | 76 Days | 111 Days |
Sector | — | Health |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $85.46, down 3.13% amid a bearish technical signal with 13 sell signals from moving averages. Recent news highlights pressure on gold miners from rising interest rates and silver's sharp decline, though some analysts see value in the sell-off. Key support lies at $84, with resistance at $86-87. The ETF offers exposure to gold mining equities but lacks disclosed fundamental ratios in this snapshot.
The outlook for GDX hinges on gold price direction and interest rate trends, with risks including metal volatility and macroeconomic headwinds. Opportunities exist if gold rebounds, but investor caution is warranted given technical weakness and mixed sentiment from institutional flows.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
